Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 ...

In the 1970s, scientists knew that some viruses and chemicals caused cancer, but they didn’t know how. Arnold Levine, a biologist currently at the Institute for Advanced Study researched DNA viruses ...

This review illustrates how the nuclear phosphoinositide-p53 signalosome integrates lipid signaling and p53 function to regulate cancer cell motility. The figure contrasts the tumor-suppressive ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

Toxicologists have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes. The gene coding for the ...

The p53 tumor suppressor protein is encoded by TP53, the most frequently mutated gene in cancer. A review article published in Nature Reviews Clinical Oncology by Professor Klas G Wiman and colleagues ...

Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis. This is an ASCO Meeting Abstract from the 2024 ...

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...